Insight to Physiology and Pathology of Zinc(II) Ions and Their
Actions in Breast and Prostate Carcinoma

J 2011

Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma

GUMULEC, Jaromír, Michal MASAŘÍK, S. KRIZKOVA, V. ADAM, J. HUBÁLEK et. al.

Základní údaje

Originální název

Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma

Autoři

GUMULEC, Jaromír (203 Česká republika, garant, domácí), Michal MASAŘÍK (203 Česká republika, domácí), S. KRIZKOVA (203 Česká republika), V. ADAM (203 Česká republika), J. HUBÁLEK (203 Česká republika), J. HRABETA (203 Česká republika), T. ECKSCHLAGER (203 Česká republika), M. STIBOROVA (203 Česká republika) a René KIZEK (203 Česká republika)

Vydání

Current Medicinal Chemistry, 2011, 0929-8673

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.859

Kód RIV

RIV/00216224:14110/11:00050258

Organizační jednotka

Lékařská fakulta

UT WoS

000299031000003

Klíčová slova anglicky

Zinc; Cancer; Prostate Carcinoma; Breast Carcinoma; Homeostasis; Low Molecular Mass Thiols; Metallothionein; Glutathione; Zinc Intake; Apoptosis; ZnT and ZIP transporters

Příznaky

Mezinárodní význam

Změněno: 23. 3. 2012 14:12, Mgr. Michal Petr

Anotace

V originále

Zinc(II) ions contribute to a number of biological processes e.g. DNA synthesis, gene expression, enzymatic catalysis, neurotransmission, and apoptosis. Zinc(II) dysregulation, deficiency and over-supply are connected with various diseases, particularly cancer. 98 % of human body zinc(II) is localized in the intracellular compartment, where zinc(II) is bound with low affinity to metallothionein (MT). Zinc transporters ZIP and ZnT maintain transmembrane transport from/to cells or organelles. Imbalance of their regulation is described in cancers, particularly prostate (down-regulated zinc transporters ZIP1, 2, 3 and ZnT-2) and breast, notably its high-risk variant (up-regulated ZIP6, 7, 10). As a result, intracellular and even blood plasma zinc(II) levels are altered. MT protects cells against oxidative stress, because it cooperates with reduced glutathione (GSH). Recent studies indicate elevated serum level of MT in a number of malignancies, among others in breast, and prostate. MT together with zinc(II) affect apoptosis and proliferation, thus together with its antioxidative effects it may affect cancer. To date, only little is known about the influence of zinc(II) and MT on cancer, while these compounds may play an important role in pathogenesis. This review concludes current data regarding the impact of zinc(II) on the pathogenesis of breast and prostate cancers with potential outlines of new, targeted therapy and prevention. Moreover, blood plasma zinc(II) and MT levels and dietary zinc(II) intake are discussed in relation to breast and prostate cancer risk.

Návaznosti

GP301/09/P436, projekt VaV

Název: Analýza metalothioneinu u karcinomu prostaty na úrovni DNA, RNA a proteinu.

Investor: Grantová agentura ČR, Analýza metalothioneinu u karcinomu prostaty na úrovni DNA, RNA a proteinu

NS10200, projekt VaV

Název: Nádorové markery, jejich stanovení a korelace s karcinomem prostaty

Investor: Ministerstvo zdravotnictví ČR, Nádorové markery, jejich stanovení a korelace s karcinomem prostaty

Citovat

GUMULEC, Jaromír, Michal MASAŘÍK, S. KRIZKOVA, V. ADAM, J. HUBÁLEK, J. HRABETA, T. ECKSCHLAGER, M. STIBOROVA a René KIZEK. Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma. Current Medicinal Chemistry. 2011, roč. 18, č. 33, s. 5041-5051. ISSN 0929-8673.

@article{963486,
   author = {Gumulec, Jaromír and Masařík, Michal and Krizkova, S. and Adam, V. and Hubálek, J. and Hrabeta, J. and Eckschlager, T. and Stiborova, M. and Kizek, René},
   article_number = {33},
   keywords = {Zinc; Cancer; Prostate Carcinoma; Breast Carcinoma; Homeostasis; Low Molecular Mass Thiols; Metallothionein; Glutathione; Zinc Intake; Apoptosis; ZnT and ZIP transporters},
   language = {eng},
   issn = {0929-8673},
   journal = {Current Medicinal Chemistry},
   title = {Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma},
   volume = {18},
   year = {2011}
}

TY  - JOUR
ID  - 963486
AU  - Gumulec, Jaromír - Masařík, Michal - Krizkova, S. - Adam, V. - Hubálek, J. - Hrabeta, J. - Eckschlager, T. - Stiborova, M. - Kizek, René
PY  - 2011
TI  - Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
JF  - Current Medicinal Chemistry
VL  - 18
IS  - 33
SP  - 5041-5051
EP  - 5041-5051
SN  - 09298673
KW  - Zinc
KW  - Cancer
KW  - Prostate Carcinoma
KW  - Breast Carcinoma
KW  - Homeostasis
KW  - Low Molecular Mass Thiols
KW  - Metallothionein
KW  - Glutathione
KW  - Zinc Intake
KW  - Apoptosis
KW  - ZnT and ZIP transporters
N2  - Zinc(II) ions contribute to a number of biological processes e.g. DNA synthesis, gene expression, enzymatic catalysis, neurotransmission, and apoptosis. Zinc(II) dysregulation, deficiency and over-supply are connected with various diseases, particularly cancer. 98 % of human body zinc(II) is localized in the intracellular compartment, where zinc(II) is bound with low affinity to metallothionein (MT). Zinc transporters ZIP and ZnT maintain transmembrane transport from/to cells or organelles. Imbalance of their regulation is described in cancers, particularly prostate (down-regulated zinc transporters ZIP1, 2, 3 and ZnT-2) and breast, notably its high-risk variant (up-regulated ZIP6, 7, 10). As a result, intracellular and even blood plasma zinc(II) levels are altered. MT protects cells against oxidative stress, because it cooperates with reduced glutathione (GSH). Recent studies indicate elevated serum level of MT in a number of malignancies, among others in breast, and prostate. MT together with zinc(II) affect apoptosis and proliferation, thus together with its antioxidative effects it may affect cancer. To date, only little is known about the influence of zinc(II) and MT on cancer, while these compounds may play an important role in pathogenesis. This review concludes current data regarding the impact of zinc(II) on the pathogenesis of breast and prostate cancers with potential outlines of new, targeted therapy and prevention. Moreover, blood plasma zinc(II) and MT levels and dietary zinc(II) intake are discussed in relation to breast and prostate cancer risk.
ER  -

GUMULEC, Jaromír, Michal MASAŘÍK, S. KRIZKOVA, V. ADAM, J. HUBÁLEK, J. HRABETA, T. ECKSCHLAGER, M. STIBOROVA a René KIZEK. Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma. \textit{Current Medicinal Chemistry}. 2011, roč.~18, č.~33, s.~5041-5051. ISSN~0929-8673.

Podrobný výpis o publikaci